Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and associations with p53 genotype/phenotype

Journal of Clinical Pathology - Molecular Pathology

Volumn 51, Issue 5, 1998, Pages 254-261

  De Angelis, P M ^a   Stokke, T ^b   Thorstensen, L ^b   Lothe, R A ^b   Clausen, O P F ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Apoptosis; Bcl 2 related family of protein; Colorectal cancer; p53

Indexed keywords

DNA FRAGMENT; PROTEIN P53; REGULATOR PROTEIN;

APOPTOSIS; ARTICLE; COLORECTAL CANCER; FRAMESHIFT MUTATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PLOIDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031784625     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.51.5.254     Document Type: Article

References (38)

1. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997;88:347-54.
2. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997;3:614-20.
3. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
4. Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc. Natl Acad Sci USA 1995;92:7834-8.
5. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88:386-401.
6. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993;74:777-9.
7. Hague A, Moorghen M, Hicks D, et al. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994;9:3367-70.
8. Bronner MP, Culin C, Reed JC, et al. The bcl-2 protooncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995;146:20-6.
9. Sinicrope FA, Ruan SB, Cleary KR, et al. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-24.
10. Krajewska M, Moss SF, Krajewski S, et al. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 1996;56:2422-7.
11. Bargou RC, Daniel PT, Mapara MY, et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-a expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995;60:854-9.
12. Xie X, De Angelis P, Clausen OPF, et al. Bax expression has prognostic significance which is enhanced when combined with AgNOR counts in glottic carcinomas. Br J Cancer 1998;78:100-5.
13. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-7.
14. Shaw P, Bovey R, Tardy S, et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992;89:4495-9.
15. Levine A. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
16. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
17. Miyashita T, Reed J. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
18. Miyashita T, Harigai M, Hanada M, et al. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
19. Friedlander P, Haupt Y, Prives C, et al. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 1996;16:4961-71.
20. Ludvig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996;16:4952-60.
21. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
22. Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994;145:1323-36.
23. De Angelis P, Stokke T, Smedshammer L, et al. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 1995;72:307-11.
24. De Angelis, P, Stokke, T, Smedshammer L, et al. p53 expression is associated with a high degree of tumor DNA aneuploidy and incidence of p53 gene mutation, and is localized to the aneuploid component in colorectal carcinomas. Int J Oncol 1993;3:305-12.
25. Hovig E, Smith-Sorensen B, Brogger A, et al. Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection. Mutat Res 1991;262:63-71.
26. Børresen-Dale A-L, Lystad S, Langerod A. Temporal temperature gradient gel electrophoresis (TTGE) compared with denaturing gradient gel electrophoresis (DGGE) and constant denaturant gel electrophoresis (CDGE) in mutation screening. Bioradiation 1997;95:12-13.
27. Andersen TT, Børresen A-L. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Diagn Mol Pathol 1995;4:203-11.
28. Børreson-Dale A-L, Lystad S, Langerod A. Temporal temperature gradient gel electrophoresis on the dcode system. Bioradiations 1997;99:12-13.
29. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-9.
30. Baretton GB, Diebold J, Christoforis G, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 1996;77:255-64.
31. van de Schepop HAM, De Jong JS, van Diest PJ, et al. Counting of apoptotic cells: a methodological study in invasive breast cancer. J Clin Pathol: Mol Pathol 1996;49:M214-17.
32. Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 1994;54:5501-7.
33. Merritt AJ, Potten CS, Watson AJM, et al. Differential expression of bcl-2 in intestinal epithelia. Correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J Cell Sci 1995;108:2261-71.
34. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and the prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
35. Ayhan A, Yasui W, Yokozaki H, et al. Loss of heterozygosity at the bcl-2 gene locus and expression of bcl-2 in human gastric and colorectal carcinomas. Jpn J Cancer Res 1994;85:584-91.
36. Meijerink JPP, Smetsers TFCM, Sloetjes AW, et al. Bax mutations in cell lines derived from hematological malignancies. Leukemia 1995;9:1828-32.
37. Ried T, Knutzen R, Steinbeck R, et al. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosomes Cancer 1996;15:234-15.
38. Haldar S, Negrini M, Monne M, et al. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54: 2095-7. Dye terminators.